{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=vedolizumab",
    "query": {
      "intervention": "vedolizumab"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 80,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=vedolizumab&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T02:20:05.477Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00783718",
      "title": "Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "vedolizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 895,
      "start_date": "2009-01",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2014-07-18",
      "last_synced_at": "2026-09-02T02:20:05.477Z",
      "location_count": 102,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Montebello, California + 82 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Montebello",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00783718"
    },
    {
      "nct_id": "NCT03553472",
      "title": "Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Herpes Zoster",
        "Inflammatory Bowel Diseases",
        "Crohn Disease",
        "Ulcerative Colitis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "35 Years to 49 Years"
      },
      "enrollment_count": 97,
      "start_date": "2018-01-01",
      "completion_date": "2019-05-31",
      "has_results": false,
      "last_update_posted_date": "2019-06-19",
      "last_synced_at": "2026-09-02T02:20:05.477Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03553472"
    },
    {
      "nct_id": "NCT03056924",
      "title": "Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Inflammatory Bowel Diseases"
      ],
      "interventions": [
        {
          "name": "Pneumococcal Pneumonia vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis B vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Boston Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 173,
      "start_date": "2017-07-05",
      "completion_date": "2019-01-15",
      "has_results": false,
      "last_update_posted_date": "2019-12-30",
      "last_synced_at": "2026-09-02T02:20:05.477Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03056924"
    },
    {
      "nct_id": "NCT04372108",
      "title": "A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Crohn Disease",
        "Colitis, Ulcerative"
      ],
      "interventions": [
        {
          "name": "Ustekinumab",
          "type": "DRUG"
        },
        {
          "name": "Other Biologic Therapies",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Scientific Affairs, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1536,
      "start_date": "2021-06-24",
      "completion_date": "2030-08-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-09-02T02:20:05.477Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04372108"
    },
    {
      "nct_id": "NCT04909359",
      "title": "Characterization of CD Responders to Vedolizumab",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Crohn Disease",
        "Ulcerative Colitis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 51,
      "start_date": "2015-08-25",
      "completion_date": "2020-05-18",
      "has_results": false,
      "last_update_posted_date": "2021-06-01",
      "last_synced_at": "2026-09-02T02:20:05.477Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04909359"
    },
    {
      "nct_id": "NCT02423512",
      "title": "The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Inflammatory Bowel Disease",
        "Crohn's Disease",
        "Ulcerative Colitis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2015-06",
      "completion_date": "2017-06-13",
      "has_results": false,
      "last_update_posted_date": "2017-09-13",
      "last_synced_at": "2026-09-02T02:20:05.477Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02423512"
    },
    {
      "nct_id": "NCT02630966",
      "title": "Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Vedolizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 34,
      "start_date": "2016-08-10",
      "completion_date": "2018-11-14",
      "has_results": true,
      "last_update_posted_date": "2019-11-19",
      "last_synced_at": "2026-09-02T02:20:05.477Z",
      "location_count": 3,
      "location_summary": "Nashville, Tennessee • Southlake, Texas • Seattle, Washington",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Southlake",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02630966"
    },
    {
      "nct_id": "NCT03961295",
      "title": "A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Vedolizumab SC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2018-02-22",
      "completion_date": "2018-08-28",
      "has_results": true,
      "last_update_posted_date": "2019-11-13",
      "last_synced_at": "2026-09-02T02:20:05.477Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03961295"
    },
    {
      "nct_id": "NCT02790138",
      "title": "A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pouchitis"
      ],
      "interventions": [
        {
          "name": "Vedolizumab Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ciprofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Vedolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 102,
      "start_date": "2016-10-12",
      "completion_date": "2021-02-02",
      "has_results": true,
      "last_update_posted_date": "2022-02-24",
      "last_synced_at": "2026-09-02T02:20:05.477Z",
      "location_count": 10,
      "location_summary": "Chicago, Illinois • Evanston, Illinois • Minneapolis, Minnesota + 7 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02790138"
    },
    {
      "nct_id": "NCT06095128",
      "title": "A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Vedolizumab",
          "type": "DRUG"
        },
        {
          "name": "Tofacitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 65,
      "start_date": "2024-06-12",
      "completion_date": "2027-07-09",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-09-02T02:20:05.477Z",
      "location_count": 37,
      "location_summary": "Dothan, Alabama • Sun City, Arizona • Los Angeles, California + 33 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06095128"
    }
  ]
}